12.13
Infusión intravenosa a dosificación oral: métodos de conversión
El desarrollo de formulaciones de liberación prolongada ha facilitado la transición de la administración intravenosa a la administración oral, ofrecie…
La disponibilidad de formulaciones de liberación prolongada ha permitido la conversión de infusiones intravenosas a medicamentos orales.
Suspender la infusión intravenosa disminuye la concentración plasmática de fármacos mediante la cinética de eliminación de primer orden.
La dosificación oral debe contrarrestar esta disminución para alcanzar una nueva concentración estable.
Para los pacientes estabilizados con infusión intravenosa, se utilizan dos métodos para calcular los regímenes de dosificación oral.
El primer método asume que la concentración plasmática estable tras la infusión intravenosa coincide con la concentración media deseada de fármacos plasmáticos en estado estacionario tras múltiples dosis orales. Aquí, la concentración media en estado estacionario depende de la forma salina del fármaco, la biodisponibilidad fraccionada, la eliminación y la tasa de dosificación.
Una infusión intravenosa de aminofilina a 34 mg por hora corresponde a una dosis oral de teofilina de 28,9 mg por hora. Durante 24 horas, esto da una dosis diaria total de teofilina de unos 700 mg.
El segundo método equipara la tasa de infusión intravenosa con la dosificación oral deseada. Aquí, la dosificación oral puede calcularse simplemente multiplicando la dosis total diaria intravenosa por la forma salina del fármaco.
View the full transcript and gain access to JoVE Core videos
Q1: Why is converting from IV infusion to oral medication necessary?
Extended-release formulations enable safer, more convenient patient transitions from IV to oral therapy while maintaining therapeutic drug levels. This shift improves quality of life by allowing self-administration at home rather than requiring continuous hospital infusions. The conversion preserves efficacy and prevents adverse effects through careful pharmacokinetic management.
Q2: What happens to drug concentration when an IV infusion is discontinued?
Discontinuing IV infusion causes plasma drug concentration to decline following first-order elimination kinetics. Oral dosing must be carefully calculated to counteract this drop and establish a new steady state. Extended-release formulations help by allowing steady drug release over time, mimicking constant levels achieved with IV infusions.
Q3: What is the first method for calculating oral dosage during IV-to-oral conversion?
The first method matches the steady-state plasma concentration achieved with IV infusion to the desired average concentration with oral dosing. This calculation incorporates the drug's salt form, fractional bioavailability, clearance, and dosing rate. For example, an IV aminophylline infusion of 34 mg/hour converts to approximately 700 mg daily oral theophylline dose.
Q4: How does the second conversion method differ from the first?
The second method directly equates the IV infusion rate to the desired oral dosing rate by multiplying the total daily IV dose by the drug's salt form. While simpler to apply, this approach does not account for differences in bioavailability or dosing schedule effects, potentially leading to inaccuracies in maintaining therapeutic drug levels compared to the first method.
Q5: What parameters must be considered when calculating oral dosage from IV infusion?
Critical parameters include the drug's salt factor, fractional bioavailability, clearance rate, and desired dosing frequency. For theophylline with 100% bioavailability, a 28.9 mg/hour IV infusion rate yields approximately 700 mg daily oral dose, often divided into two 350 mg controlled-release doses administered every 12 hours to maintain therapeutic levels.
Q6: Why are extended-release formulations important for IV-to-oral conversion?
Extended-release formulations enable steady drug release over extended periods, mimicking constant plasma levels achieved with IV infusions. This sustained delivery maintains therapeutic drug concentrations throughout the dosing interval, reducing fluctuations and improving patient compliance compared to immediate-release oral medications requiring frequent dosing.
Q7: What role does bioavailability play in converting IV to oral dosing?
Bioavailability determines how much oral drug reaches systemic circulation compared to IV administration. The first conversion method accounts for bioavailability differences through the fractional bioavailability factor, ensuring equivalent therapeutic exposure. Ignoring bioavailability, as in the simpler second method, may result in subtherapeutic or toxic drug levels.